Novartis has the most new drugs approved, and Roche's new drugs have the highest value!

Based on the data generated by Evaluate Pharma, Fierce Pharma’s team carefully studied the new drug approvals recently obtained by 11 of the world’s highest revenue drugmakers. Specifically, the data highlights the dollar value of drugs launched in the industry in the past five years and analyzes how these new drugs fit each company's overall product portfolio. Evaluate data shows that Novartis is the company with the most new drugs approved. The company has launched 12 new drugs in the past five years. Bristol Myers Squibb (Bristol Myers Squibb) has only launched three low-end drugs, all of which benefit from it. Acquisition of Celgene. Nevertheless, because some new drugs did not meet expectations, the number of new drugs on the market may not necessarily match the value.

In terms of value indicators, Roche ranks first. The company has launched eight products in the past five years, valued at US$99.78 billion. Evaluate's data shows that AbbVie and AstraZeneca each launched five products, and their net present values are equally impressive. But these data do not include COVID-19 vaccines or treatments. Especially Pfizer, its mRNA vaccine cooperation with biotech is expected to become the world's best-selling drug this year.

According to the value of new drugs approved in the past 5 years and according to data from Evaluate, the R&D strength of pharmaceutical giants is ranked as follows: Roche, AbbVie, AstraZeneca, Eli Lilly, Novartis, GlaxoSmithKline, Johnson & Johnson, Pfizer, Bristol-Myers Bristol-Myers Squibb, Sanofi, Merck.

1.Roche
Approved in the past 5 years: 8
Value: $99.77 billion
Percent of value: 45.9%

With the global anti-cancer drug giants Herceptin, Avastin and Rituxan being challenged by biosimilars, Roche has always relied on the one launched since 2012. Approve newer drugs to drive growth. Most of these products have been approved in the past 5 years and belong to the fields of oncology and neuroscience. Since 2016, Roche has launched a total of 8 new molecular entities. According to recent statistics from EvaluatePharma and Evaluate Vantage, the total net value of these drugs is US$99.77 billion, accounting for 46% of the company's total drug portfolio.

2. AbbVie
Approved in the past 5 years: 5
Value: $76.4 billion
Percentage of value: 36%

The number of new AbbVie drugs approved is relatively small, but the current value is as high as US$76.4 billion. Therefore, the top priority of AbbVie's new drug is quality, not quantity. According to data from EvaluatePharma and Evaluate Vantage, the total value of AbbVie's listed drugs is US$209.5 billion. Drugs approved in the past five years accounted for 36% of the total. This good prospect is largely due to AbbVie’s emerging immunology superstars Rinvoq and Skyrizi, the company hopes that when the world’s best-selling drug Humira expires in 2023, the two Medicine will fill the gap.

3. AstraZeneca
Approved in the past 5 years: 5
Value: $45.53 billion
Percent of value: 27.8%

When CEO Pascal Soriot joined AstraZeneca in 2012, the British pharmaceutical company was suffering from the expiration of key patents and needed new drugs. At the end of 2018, thanks to the launch of a series of new products, the drugmaker successfully resumed its growth. In the past five years, the company has indeed received FDA approval for five new molecules. According to data from EvaluatePharma and Evaluate Vantage, the net present value of these drugs totals $45.53 billion. In 2017, the company received FDA-approved PD-L1 inhibitor Imfinzi, blood cancer drug Calquence, and asthma injection drug Fasenra. These drugs have either reached amazing sales or have shown a strong momentum in the process.

4. Eli Lilly
Approved in the past 5 years: 8
Value: $38.05 billion
Percentage of value: 36%

A few years ago, Eli Lilly was one of the largest pharmaceutical companies in the portfolio that relied on old drugs the most. Recently, the company has made significant progress in changing this status quo. EvaluatePharma and Evaluate Vantage data show that now, Eli Lilly has become one of the top companies in the industry to get the most value from new products. Analysts said that the company's entire portfolio is worth $105 billion in terms of net present value, 36% of which comes from products launched in the past five years. These new drugs are worth about 38 billion U.S. dollars. Since 2016, Eli Lilly has received 8 FDA approvals, second only to Novartis and Merck, and equal to Roche. Eli Lilly's new products include immunology drug Taltz (net present value of 9.8 billion U.S. dollars) and breast cancer drug Verzenio (net present value of 17.13 billion U.S. dollars).

5. Novartis
Number of approvals in the past 5 years: 12
Value: $37.65 billion
Percentage of value: 23%

In the past five years, Novartis has obtained more than a dozen approvals, and Novartis is the leader in this regard. On this list are heavyweight drugs in the field of cell and gene therapy, such as Zolgensma. In the field of ophthalmology, it competed fiercely with Eylea, Regeneron's leading product, but due to safety issues, the latter basically withdrew from the competition. Although Novartis leads other pharmaceutical companies in the number of approvals, the company's performance is not very good in terms of the value it derives from newly approved drugs. According to a recent report by Evaluate Vantage and EvaluatePharma, overall, the company's entire drug portfolio has a net present value of $164 billion. Novartis’s new products account for approximately 23% of the total, or US$37.65 billion. Novartis gene therapy Zolgensma ranks first among the company's newly listed products with a net present value of US$7.95 billion. In 2019, the therapy was approved in patients with spinal muscular atrophy (SMA). In 2020, the therapy has global sales of US$920 million and is currently approved for the treatment of SMA patients 2 years of age and younger.

6. GlaxoSmithKline (GSK)
Number of approvals in the past 5 years: 7
Value: $30.16 billion
Percent of value: 24.46%

In the past 5 years, the new treatment has received 7 regulatory approvals. This puts it in the middle of the 11 major pharmaceutical companies. The net present value of all listed drugs of GlaxoSmithKline is US$123 billion, slightly higher than that of Eli Lilly. According to estimates by EvaluatePharma and Evaluate Vantage, nearly a quarter (about 30 billion U.S. dollars) of this comes from new GlaxoSmithKline drugs. It is worth mentioning that GlaxoSmithKline also shares revenue from two new AIDS drugs through its joint venture ViiV Healthcare. GlaxoSmithKline is relying on its vaccine business, especially Shingrix. The vaccine was first approved in 2017 to prevent shingles in adults aged 50 and over. It was recently approved by the U.S. Food and Drug Administration (FDA) for use in young patients with weakened immune functions and a higher risk of viral infection. Evaluate said that among all the latest GlaxoSmithKline drugs, the vaccine has the highest net present value of approximately $18.3 billion.

7. Johnson & Johnson
Approved in the past 5 years: 5
Value: $24.26 billion
Percent of value: 10.23%

According to a recent analysis by EvaluatePharma and Evaluate Vantage, five drugs recently approved by Johnson & Johnson have a net present value of US$24.26 billion. This accounts for approximately 10.2% of the $237 billion value of all drugs sold by Johnson & Johnson. Johnson & Johnson has been approved to treat multiple sclerosis Ponvory and non-small cell lung cancer (NSCLC) antibody Rybrevant in 2021. In May of this year, Rybrevant was approved for the treatment of a group of patients with non-small cell lung cancer with mutations in the epidermal growth factor receptor (EGFR). This drug is called exon 20, becoming the first fully human double Specific lung cancer antibody. The company said that this is also the first lung cancer drug in Johnson & Johnson's history.

8. Pfizer
Number of approvals in the past 5 years: 7
Value: $17.41 billion
Percent of value: 11.54%

Analysts paid special attention to the new molecules that have been approved in the past five years. In Pfizer's case, they include the company's rare disease drug Vyndaqel, and cancer drugs Daurismo, Lorbrena and Talzenna. According to analysts, the total value of seven new drugs approved by Pfizer recently is $17.4 billion. The net present value of all the company's products is $150.87 billion, and Pfizer's new products account for 12% of the total market value.

9. Bristol Myers Squibb
Number of approvals in the past 5 years: 3
Value: $15.49 billion
Percent of value: 9.33%

In the past five years, Bristol-Myers Squibb has only promoted three new drugs to pass FDA approval. Each transaction has benefited from the huge merger with Celgene, which may indicate the reason why Bristol-Myers Squibb executives felt the need for an acquisition. Analysts at EvaluatePharma and Evaluate Vantage said that the net present value of all listed drugs of Bristol-Myers Squibb is $166.12 billion. Its three newly listed drugs, Zeposia, Breyanzi and abecma, have a market value of approximately US$15.49 billion, accounting for 9.3% of the total market value.

10. Sanofi
Approved in the past 5 years: 6
Value: $6.13 billion
Percent of value: 4%

EvaluatePharma and Evaluate Vantage data show that in the past five years, Sanofi has received six new drugs or vaccine approvals. Analysts said that although this figure is in the middle of the competition, the net present value of Sanofi's new drug is only about 6 billion US dollars. But importantly, these data do not include Dupixent, a key atopic dermatitis and immunological blockbuster product, because Sanofi’s partner Regeneron supported the drug’s approval to the FDA. If Dupixent's data is included, Sanofi's overall positioning may be greatly improved. Sanofi's approved products in 2017 will achieve amazing sales. Sanofi said that Dupixent's sales in 2020 will be 3.53 billion euros ($4.15 billion), and company executives are confident that the drug's peak sales can reach 10 billion euros.

11. Merck & Co.
Number of approvals in the past 5 years: 9
Value: $3.8 billion
Percent of value: 2%

In the past five years, Merck has obtained nine new drug approvals, and Merck is working hard to find a successor to the immuno-oncology superstar Keytruda. According to the analysis of EvaluatePharma and Evaluate Vantage, the net present value of Merck's drug portfolio is as high as 230.7 billion U.S. dollars, but only 3.8 billion U.S. dollars of this comes from drugs approved in the past five years. The company's anti-cancer product, Keytruda, was approved in 2014 and has many years of patent protection. In 2020, its revenue reached 14.4 million U.S. dollars, and in the next few years, it will remain at the forefront of the sales rankings. In December 2017, Pfizer's diabetes drug stegllatro passed the FDA review and the combination therapy of Steglujan and Segluromet. Evaluate said the three drugs combined provide a net present value of US$750 million.